0002153598 2026-09-23 2026-09-23 0002153598 dei:BusinessContactMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt75PercentOfMaximumMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt25PercentOfMaximumMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt50PercentOfMaximumMember 2026-09-23 2026-09-23 0002153598 ck0002153598:LoansMember ck0002153598:FrazierLifeSciencesHoldingsIILLCMember 2026-09-23 2026-09-23 0002153598 ck0002153598:PrivatePlacementSharesMember ck0002153598:FrazierLifeSciencesHoldingsIILLCMember 2026-09-23 2026-09-23 0002153598 spac:CommonSharesMember ck0002153598:FrazierLifeSciencesHoldingsIILLCMember 2026-09-23 2026-09-23 0002153598 ck0002153598:UnderwritingCommissionsMember ck0002153598:FrazierLifeSciencesHoldingsIILLCMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:DilutionToPublicShareholdersMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:DilutionToPublicShareholdersMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:NetProceedsFromThisOfferingAndTheSaleOfThePrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:NetProceedsFromThisOfferingAndTheSaleOfThePrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:OfferingCostsAccruedForOrPaidInAdvanceExcludedFromTangibleBookValueMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:OfferingCostsAccruedForOrPaidInAdvanceExcludedFromTangibleBookValueMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:DeferredUnderwritingDiscountMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:DeferredUnderwritingDiscountMember 2026-09-23 2026-09-23 0002153598 spac:ShareholderRedemptionsMember spac:NoRedemptionMember 2026-09-23 2026-09-23 0002153598 spac:ShareholderRedemptionsMember spac:RedemptionAt100PercentOfMaximumMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:OrdinarySharesOfferedAndSaleOfPrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:OrdinarySharesOfferedAndSaleOfPrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:PrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:PrivatePlacementSharesMember 2026-09-23 2026-09-23 0002153598 spac:NoRedemptionMember ck0002153598:OrdinarySharesRedeemedMember 2026-09-23 2026-09-23 0002153598 spac:RedemptionAt100PercentOfMaximumMember ck0002153598:OrdinarySharesRedeemedMember 2026-09-23 2026-09-23 0002153598 spac:CommonSharesMember 2026-09-23 2026-09-23 0002153598 spac:FounderSharesMember 2026-09-23 2026-09-23 0002153598 ck0002153598:PrivatePlacementSharesMember 2026-09-23 2026-09-23 shares iso4217:USD iso4217:USD shares Frazier Life Sciences Acquisition Corp. II 0002153598 false CA CA S-1 E9 6770 98-1964369 1001 Page Mill Road, Building 4, Suite 200B Palo Alto 93404 650 325-5156 Albert Cha 1001 Page Mill Road, Building 4, Suite 200B Palo Alto 93404 650 325-5156 Non-accelerated Filer true true false <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">If we are unable to complete our initial business combination within 24 months from the closing of this offering, or such other time period in which we must complete an initial business combination pursuant to an amendment to our amended and restated memorandum and articles of association, which we refer to as the completion window, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain conditions as further described herein. We may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension. </div> P24M P24M true We may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. true true true true 10 10 10 10 10 7.6 7.02 2.98 6.08 3.92 4.26 5.74 -0.68 10.68 true Limited Liability Company our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. As a result, our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination opportunities to us or to any other special purpose acquisition company with which they may become involved. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target. <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial;font-weight:bold">Sponsor Information </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">Our sponsor is a Cayman Islands limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Cayman <span style="-sec-ix-hidden:hidden171875133;display:inline;">Limited Liability Companies</span> Act and other applicable law, our sponsor’s business is focused on investing in our company. The managing member of our sponsor is Albert Cha, M.D., Ph.D., our Chief Executive Officer and a member of our board of directors. Dr. Cha controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, FLSPF owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor. </div><div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates: </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC and other initial shareholders</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">1,875,000 Class B ordinary shares, of which 1,683,749 Class B ordinary shares are held by our sponsor and 191,251 Class B ordinary shares are held by our independent directors and Chief Financial Officer.</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$25,000 (approximately $0.013 per share after giving effect to the share forfeiture)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">300,000 private placement shares</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$3,000,000 ($10.00 per share)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, an affiliate thereof, or our officers and directors</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Loans to finance transaction costs in connection with an intended initial business combination</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Frazier Life Sciences</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Holdings II LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Up to $300,000 under an unsecured, <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</span> bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $750,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Holders of Class B ordinary shares</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Anti-dilution protection upon conversion into Class A ordinary shares at a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> ratio</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> basis upon conversion</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, our officers or directors, or affiliates thereof</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">related to identifying, investigating, negotiating and completing an initial business combination</div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial;font-weight:bold">Sponsor Information </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">Our sponsor is a Cayman Islands limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Cayman <span style="-sec-ix-hidden:hidden171875133;display:inline;">Limited Liability Companies</span> Act and other applicable law, our sponsor’s business is focused on investing in our company. The managing member of our sponsor is Albert Cha, M.D., Ph.D., our Chief Executive Officer and a member of our board of directors. Dr. Cha controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, FLSPF owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor. </div><div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates: </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC and other initial shareholders</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">1,875,000 Class B ordinary shares, of which 1,683,749 Class B ordinary shares are held by our sponsor and 191,251 Class B ordinary shares are held by our independent directors and Chief Financial Officer.</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$25,000 (approximately $0.013 per share after giving effect to the share forfeiture)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">300,000 private placement shares</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$3,000,000 ($10.00 per share)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, an affiliate thereof, or our officers and directors</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Loans to finance transaction costs in connection with an intended initial business combination</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Frazier Life Sciences</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Holdings II LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Up to $300,000 under an unsecured, <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</span> bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $750,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Holders of Class B ordinary shares</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Anti-dilution protection upon conversion into Class A ordinary shares at a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> ratio</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> basis upon conversion</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, our officers or directors, or affiliates thereof</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">related to identifying, investigating, negotiating and completing an initial business combination</div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> Sponsor Our sponsor is a Cayman Islands limited liability company and was formed to invest in us. Although our sponsor is permitted to undertake any activities permitted under the Cayman <span style="-sec-ix-hidden:hidden171875133;display:inline;">Limited Liability Companies</span> Act and other applicable law, our sponsor’s business is focused on investing in our company. The managing member of our sponsor is Albert Cha, M.D., Ph.D., our Chief Executive Officer and a member of our board of directors. Dr. Cha controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, FLSPF owns 100% of the economic rights attributable to the founder shares and private placement shares held by our sponsor. Cayman Islands limited liability company The managing member of our sponsor is Albert Cha, M.D., Ph.D., our Chief Executive Officer and a member of our board of directors. Dr. Cha controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. Albert Cha, M.D., Ph.D. Albert Cha, M.D., Ph.D. Chief Executive Officer <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC and other initial shareholders</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">1,875,000 Class B ordinary shares, of which 1,683,749 Class B ordinary shares are held by our sponsor and 191,251 Class B ordinary shares are held by our independent directors and Chief Financial Officer.</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$25,000 (approximately $0.013 per share after giving effect to the share forfeiture)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">300,000 private placement shares</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">$3,000,000 ($10.00 per share)</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, an affiliate thereof, or our officers and directors</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Loans to finance transaction costs in connection with an intended initial business combination</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Frazier Life Sciences</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Holdings II LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Up to $300,000 under an unsecured, <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</span> bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $750,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:22%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:54%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES<br/>ISSUED OR TO BE ISSUED</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">CONSIDERATION PAID OR<br/>TO BE PAID</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Holders of Class B ordinary shares</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Anti-dilution protection upon conversion into Class A ordinary shares at a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> ratio</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top">Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">one-to-one</div></div> basis upon conversion</td></tr> <tr style="font-size:1pt"> <td style="height:9pt"></td> <td colspan="2" style="height:9pt"></td> <td colspan="2" style="height:9pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top">Frazier Life Sciences Holdings II LLC, our officers or directors, or affiliates thereof</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:top">Repayment in cash</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">out-of-pocket</div></div> expenses</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">related to identifying, investigating, negotiating and completing an initial business combination</div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> 1875000 1875000 25000 25000 300000 3000000 3000000 300000 The founder shares are not transferable or saleable until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</span> dayperiod commencing at least 180 days after the completion of our initial business combination. Initial shareholders Transfers are permitted (a) to us or to our officers or directors, advisors or consultants, any affiliate or family member of any of our officers or directors, advisors or consultants, any members or partners of our sponsor or their affiliates and funds and accounts advised by such members or partners, any affiliates of our sponsor, or any employees of such affiliates, (b) in the case of an individual, as a gift to such person’s immediate family or to atrust, the beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization, (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such person, (d) in the case of an individual, pursuant to a qualified domestic relations order, (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in connection with the consummation of a business combination at prices no greater than the price at which the shares were originally purchased, (f) by virtue of the laws of the Cayman Islands or our Sponsor’s limited liability company agreement upon dissolution of our sponsor, (g) in the event of our liquidation prior to our consummation of our initial business combination, (h) in the event that, subsequent to our consummation of an initial business combination, we complete a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property, (i) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a) through (h) above, or (j) pursuant to an order of a court or regulatory agency; provided, however, that in the case of clauses (a) through (e) or (i) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreements. The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination. Frazier Life Sciences Holdings II LLC Same as above. <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr style="vertical-align:TOP"> <td style="width:38%"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; text-indent: -2%; font-size: 9.5pt; font-family: Arial; line-height: normal;">Redemption of public shares and distribution and liquidation if no initial business combination: </div></td> <td>Our amended and restated memorandum and articles of association provide that we will have only the completion window to complete our initial business combination. If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject, in each case to our obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Arial; font-size: 9.5pt; line-height: normal;">Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares and private placement shares held by them if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if they acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the completion window. The underwriters have agreed to waive their rights to their deferred underwriting commission held in the trust account in the event we do not complete our initial business </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0%; font-size: 9.5pt; font-family: Arial; line-height: normal;">combination within the completion window and, in such event, such amounts will be included with the funds held in the trust account that will be available to fund the redemption of our public shares. </div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left">Our sponsor, officers and directors have agreed, pursuant to a letter agreement, that they will not propose any amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-initial</div> business combination activity, unless we provide our public shareholders with the opportunity to redeem their Class A ordinary shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described above under “<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Limitations on redemptions</div></div>.” For example, our board of directors may propose such an amendment if it determines that additional time is necessary to complete our initial business combination. In such event, we will conduct a proxy solicitation and distribute proxy materials pursuant to Regulation 14A of the Exchange Act seeking shareholder approval of such proposal, and in connection therewith, provide our public shareholders with the redemption rights described above upon shareholder approval of such amendment. </td></tr></table> Reimbursement for any <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><span style="white-space:nowrap;display:inline;">out-of-pocket</span></span> expenses related to identifying, investigating, negotiating and completing an initial business combination; <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr style="vertical-align:TOP"> <td style="width:38%"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; text-indent: -2%; font-size: 9.5pt; font-family: Arial; line-height: normal;">Conflicts of Interest: </div></td> <td><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Arial; font-size: 9.5pt; line-height: normal;">Each of our officers and directors has, and any of them in the future may have, additional fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. In addition, <span style="-sec-ix-hidden:hidden171875120;display:inline;">our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. As a result, our sponsor, officers and directors could have conflicts of interest in determining whether to present business combination</span> </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0%; font-size: 9.5pt; font-family: Arial; line-height: normal;">opportunities to us or to any other special purpose acquisition company with which they may become involved. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target. However, because the other entities to which our officers and directors currently owe fiduciary duties or contractual obligations are not themselves in the business of engaging in business combinations, and because we expect that our company will generally have priority over any other special purpose acquisition companies subsequently incorporated by our sponsor, officers or directors with respect to acquisition opportunities until we complete our initial business combination or enter into a contractual agreement that would restrict our ability to engage in material discussions regarding a potential initial business combination, we do not believe that any such potential conflicts would materially affect our ability to complete our initial business combination. </div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left">Our executive officers and our directors may have interests that differ from you in connection with the business combination, including the fact that they may lose their entire investment in us if our initial business combination is not completed, except to the extent they receive liquidating distributions from assets outside the trust account, and accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction. Additionally, the personal and financial interests of our directors and executive officers may influence their motivation in timely identifying and pursuing an initial business combination or completing our initial business combination. For example, our directors and executive officers may prioritize a prospective initial business combination with a shorter timeline to completion over another acquisition target which may be more difficult or time-intensive to consummate. Consequently, our directors’ and executive officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our shareholders’ best interest, which could negatively impact the timing for a business combination. </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left">In addition to the above, our officers and directors are not required to commit any specified amount of time to our affairs, and, accordingly, may have conflicts of interest in allocating management time among various business activities, including selecting a business combination target and monitoring the related due diligence. </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Arial; font-size: 9.5pt; line-height: normal;">Additionally, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares held by them in connection with the consummation of our initial business combination. Further, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0%; font-size: 9.5pt; font-family: Arial; line-height: normal;">any founder shares held by them if we are unable to complete our initial business combination within the completion window. With certain limited exceptions, the founder shares will not be transferable, assignable or salable by our sponsor or its permitted transferees until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-trading</div> day period commencing at least 180 days after the completion of our initial business combination. </div></td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left">Affiliates of FLS and members of our board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Our sponsor paid a nominal aggregate purchase price of $25,000 for the founder shares, or approximately $0.013 per share. Accordingly, our management team, which owns interests in our sponsor, may be more willing to pursue a business combination with a riskier or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares. </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left">In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination. </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: Arial; font-size: 9.5pt; line-height: normal;">We are not prohibited from pursuing an initial business combination or subsequent transaction with a company that is affiliated with FLS, our sponsor, founders, officers or directors; accordingly, such affiliated person(s) may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such affiliated person(s) would have interests different from our public shareholders and would likely not receive any financial benefit unless we consummated such business combination. In the event we seek to complete an initial business combination with a target that is affiliated (as defined in our amended and restated memorandum and articles of association) with our sponsor, executive officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm or an independent valuation or accounting firm stating that the </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;border-spacing:0;width:100%"> <tr> <td style="width:38%"> </td> <td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 0%; font-size: 9.5pt; font-family: Arial; line-height: normal;">consideration to be paid by us in such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. </div></td></tr></table> Each of our officers and directors has, and any of them in the future may have, additional fiduciary or contractual obligations to at least one other entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity, subject to their fiduciary duties under Cayman Islands law. If we seek shareholder approval of our initial business combination, our initial shareholders and management team have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote. true <div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">At August 21, 2026, our net tangible book deficit was $56,151, or approximately $0.03 per Class B ordinary share. The following table illustrates what the Adjusted NTBVPS at August 21, 2026 would have been to the public shareholders on a pro forma basis to give effect to this offering and the issuance of the private placement shares: </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:5%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td colspan="34" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">AS OF AUGUST 21, 2026</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">OFFERING<br/>PRICE OF<br/>$10.00<br/>PER SHARE</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="6" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">25% OF MAXIMUM<br/>REDEMPTION</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="6" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">50% OF MAXIMUM<br/>REDEMPTION</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="6" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">75% OF MAXIMUM<br/>REDEMPTION</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="6" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">MAXIMUM<br/>REDEMPTION</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NTBV</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NTBV</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">DIFFERENCE<br/>BETWEEN<br/>NTBV AND<br/>OFFERING<br/>PRICE</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NTBV</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">DIFFERENCE<br/>BETWEEN<br/>NTBV AND<br/>OFFERING<br/>PRICE</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NTBV</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">DIFFERENCE<br/>BETWEEN<br/>NTBV AND<br/>OFFERING<br/>PRICE</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NTBV</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">DIFFERENCE<br/>BETWEEN<br/>NTBV AND<br/>OFFERING<br/>PRICE</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">7.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">7.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">2.98</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">6.08</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">3.92</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">4.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">5.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(0.68</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.68</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">For each of the redemption scenarios above, the NTBV was calculated as follows: </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:35%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">NO<br/>REDEMPTIONS</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">25% OF<br/>MAXIMUM<br/>REDEMPTIONS</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">50% OF<br/>MAXIMUM<br/>REDEMPTIONS</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">75% OF<br/>MAXIMUM<br/>REDEMPTIONS</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><span style="letter-spacing: 0px; top: 0px;display:inline;"><span style="font-weight:bolder;display:inline;">MAXIMUM<br/>REDEMPTIONS</span></span></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Public offering price</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.00</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.00</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.00</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.00</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">10.00</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Net tangible book deficit before this offering</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.03</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.03</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.03</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.03</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.03</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Increase (decrease) attributable to public shareholders</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7.63</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7.05</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">6.11</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">4.29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.65</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Pro forma net tangible book value (deficit) after this offering and the sale of the private placement shares</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">6.08</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">4.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(0.68</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Dilution to public shareholders</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">2.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">2.98</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">3.92</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">5.74</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">10.68</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Percentage of dilution to public shareholders</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">24.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">29.8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">39.2</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">57.4</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">106.8</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial;text-align:center"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:35%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">NO<br/>REDEMPTIONS</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">25% OF<br/>MAXIMUM<br/>REDEMPTIONS</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">50% OF<br/>MAXIMUM<br/>REDEMPTIONS</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">75% OF<br/>MAXIMUM<br/>REDEMPTIONS</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td colspan="2" style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">MAXIMUM<br/>REDEMPTIONS</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; font-weight: bold; line-height: normal;">Numerator:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Net tangible book deficit before this offering</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(56,151</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(56,151</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(56,151</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(56,151</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">$</td> <td style="vertical-align:bottom;text-align:right">(56,151</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Net proceeds from this offering and the sale of the private placement shares <div style="font-size:75%; vertical-align:top;display:inline;font-size:7.9px">(1)</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">76,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">76,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">76,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">76,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">76,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Plus: Offering costs accrued for or paid in advance, excluded from tangible book value</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">74,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">74,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">74,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">74,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">74,628</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Less: Deferred Underwriting discount <div style="font-size:75%; vertical-align:top;display:inline;font-size:7.9px">(2)</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Less: Amounts paid for redemptions <div style="font-size:75%; vertical-align:top;display:inline;font-size:7.9px">(3)</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(18,750,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(37,500,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(56,250,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(75,000,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">73,518,477</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">54,768,477</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">36,018,477</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">17,268,477</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(1,481,523 </td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; font-weight: bold; line-height: normal;">Denominator:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Ordinary shares outstanding prior to this offering</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Ordinary shares offered and sale of private placement shares</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Private placement shares</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">300,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">300,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">300,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">300,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">300,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Less: Ordinary shares redeemed</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right">—</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(1,875,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(3,750,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(5,625,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">(7,500,000</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt;background-color:#cceeff"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">9,675,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">7,800,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">5,925,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">4,050,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right">2,175,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:3%;vertical-align:top;text-align:right"><div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(1)</div> </td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left">Expenses applied against gross proceeds include offering expenses of approximately $750,000, underwriting commissions of $1,500,000 and reimbursement by the underwriters of certain of our expenses and fees in connection with this offering of $750,000. See “Use of Proceeds.” </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:3%;vertical-align:top;text-align:right"><div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(2)</div> </td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left">Upon the consummation of our initial business combination, the deferred underwriting commissions will equal 4% of the gross proceeds <div style="display:inline;">of t</div>his offering. </td></tr></table> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:8pt;border-spacing:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:3%;vertical-align:top;text-align:right"><div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(3)</div> </td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left">If we seek shareholder approval of our initial business combination and we do not conduct redemptions or repurchases in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders, directors, executive officers or their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Proposed Business—Effecting Our Initial Business Combination—Permitted Purchases and Other Transactions with Respect to Our Securities</div></div>.” </td></tr></table> 10 10 -0.03 -0.03 7.6 -0.68 2.4 10.68 -56151 -56151 76500000 76500000 74628 74628 -3000000 -3000000 0 -75000000 73518477 -1481523 1875000 1875000 7500000 7500000 300000 300000 0 -7500000 9675000 2175000 true There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop agreements we may enter into following consummation of this offering. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to liquidate the trust account. <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial;font-weight:bold">Redemption Rights for Public Shareholders in Connection with the Completion of Our Initial Business Combination </div><div style="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">We will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares in connection with the completion of our initial business combination at a <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. </div> true <div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">Below is a table summarizing the entities to which our officers and directors currently have fiduciary duties or contractual obligations: </div><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> <table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:9.5pt;width:100%;border-spacing:0;margin:0 auto"> <tr> <td style="width:24%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:32%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:19%"></td> <td style="vertical-align:bottom;width:1%"></td> <td style="width:22%"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5px;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: Arial; font-weight: bold; line-height: normal;">INDIVIDUAL </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">ENTITY’S BUSINESS </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="border-bottom:1.00px solid #000000;vertical-align:bottom;text-align:center"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: Arial; font-weight: bold; text-align: center; line-height: normal;">AFFILIATION </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Albert Cha, M.D., Ph.D.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">FLS</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Ascendis Pharma A/S</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Investment Firm Biopharmaceuticals</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Managing Partner Chairman</td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Fran Adams</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">van den Boom and Associates LLC</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Accounting Firm</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Partner</td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Research Alliance Corp. III</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">SPAC</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Chief Financial Officer</td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Research Alliance Corp. IV</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">SPAC</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Chief Financial Officer</td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Kevin Li, M.D.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">FLS</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Angitia Biopharmaceuticals Limited</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Investment Firm Biopharmaceuticals</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Partner</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Director</div></td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Ali Jackson, J.D.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">FLS</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Investment Firm</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Vice President &amp; Counsel</td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">William C. Fairey, Jr.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Respira Therapeutics, Inc.</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Mirum Pharmaceuticals, Inc.</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Rein Therapeutics, Inc.</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Ascendis Pharma A/S</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Biotechnology Biopharmaceuticals Biopharmaceuticals Biopharmaceuticals</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Chairman</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Director</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Director</div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 9.5pt; font-family: Arial; line-height: normal;">Director</div></td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">Benjamin L. Palleiko.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">FLS</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Investment Firm</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Senior Advisor</td></tr> <tr style="font-size:1pt"> <td style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td> <td colspan="2" style="height:6pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; text-indent: -1.47em; font-size: 9.5pt; font-family: Arial; line-height: normal;">R. Scott Struthers, Ph.D.</div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Radionetics Oncology, Inc.</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Biotechnology</td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">Chairman</td></tr></table><div style="font-size:9pt;margin-top:0pt;margin-bottom:0pt"> </div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </div> <div style="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:Arial">If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of United States corporations. </div>